Compare · BDX vs PDEX
BDX vs PDEX
Side-by-side comparison of Becton Dickinson and Company (BDX) and Pro-Dex Inc. (PDEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and PDEX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $40.60B, about 202.1x PDEX ($200.9M).
- Over the past year, BDX is down 16.3% and PDEX is up 46.9% - PDEX leads by 63.2 points.
- BDX has been more active in the news (11 items in the past 4 weeks vs 1 for PDEX).
- BDX has more recent analyst coverage (25 ratings vs 0 for PDEX).
- Company
- Becton Dickinson and Company
- Pro-Dex Inc.
- Price
- $146.06-0.90%
- $61.25-1.84%
- Market cap
- $40.60B
- $200.9M
- 1M return
- +1.31%
- +1.65%
- 1Y return
- -16.27%
- +46.92%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 1
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Pro-Dex Inc.
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and maxocranial facial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
Latest BDX
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
Latest PDEX
- Chief Executive Officer Van Kirk Richard Lee Jr sold $626,248 worth of shares (10,000 units at $62.62) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 89,707 units (SEC Form 4)
- Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Pro-Dex Inc.
- Pro-Dex, Inc. Announces Fiscal 2026 Third Quarter and Nine Month Results
- Pro-Dex Inc. filed SEC Form 8-K: Leadership Update
- Pro-Dex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- Pro-Dex, Inc. Announces Acquisition of Advanced Precision Machining
- Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Pro-Dex Inc.
- Pro-Dex, Inc. Announces Fiscal 2026 Second Quarter and Six-Month Results